Production And Clarification Of Lentiviral Vectors At The 50 L Scale

As the demand for gene therapies and viral vector-based vaccines continues to grow, scalable manufacturing solutions become crucial for clinical and commercial success. In this application note, we detail the production and clarification of lentiviral vectors (LV) encoding anti-CD19 chimeric antigen receptor (LV-αCD19CAR) using the CTS™ LV-MAX™ Production System.

Scaling up to a 50 L capacity with Thermo Fisher Scientific's DynaDrive™ and HyPerforma™ Single-Use Bioreactors (S.U.B.s), this study demonstrates the efficiency and robustness of the LV-MAX system. Additionally, we explore two distinct scalable clarification methods: one leveraging depth filtration and the other employing the DynaSpin™ Single-Use Centrifuge for streamlined LV harvest. Both processes are evaluated for yield, titer, and scalability, providing guidance for optimizing lentiviral vector production workflows. These results highlight the versatility and scalability of the LV-MAX platform, offering valuable insights for gene therapy developers.